A B S T R A C T The concentration of a2-plasmin inhibitor in blood plasma is higher than that in serum obtained from the blood clotted in the presence ofcalcium ions, but is the same as that in serum obtained in the absence of calcium ions.
INTRODUCTION
The dissolution of fibrin deposits or thrombin in vivo is achieved by plasmin formed from plasminogen by plasminogen activator that has been added extrinsically for the therapeutic purposes (urokinase and streptokinase) or endogenously generated in the vascular trees (blood activators or vascular activator). Regardless of the manner in which plasminogen is activated, disReceived for publication 9 July 1979 and in revised form I October 1979. 290 solution of fibrin (fibrinolysis) is believed to be checked or retarded by natural inhibitors of fibrinolysis.
Natural inhibitors of fibrinolysis inhibit the activation of plasminogen to plasmin (inhibitor of plasminogen activation or activator inhibitor) or act upon the plasmin already formed (plasmin inhibitors). Although the presence of the former inhibitors in plasma (1) has not been fully substantiated, the presence of plasmin inhibitors has been firmly established (2) .
Among various proteinase inhibitors capable of inhibiting plasmin activity, two inhibitors, a2-plasmin inhibitor (a2PI)1 and a2-macroglobulin are considered to be physiologically most important (2) . Plasmin generated in a plasma milieu is effectively inhibited by these two inhibitors, therefore fibrinogenolysis does not occur under these conditions.
When fibrin is formed, plasminogen activators and plasminogen are adsorbed to fibrin and plasminogen activation takes place on fibrin molecules to exert an effective fibrinolysis. This process of fibrinolysis is efficiently inhibited by a2PI but not by a2-macroglobulin (2, 3) . This hypothesis was substantiated by the discovery ofcongenital deficiency ofa2PI (4) . The efficient inhibition of fibrinolysis by a2PI has been attributed to the inhibition of binding of plasminogen to fibrin by a2PI (2, 3) in addition to the rapid inactivation of plasmin formed during plasminogen activation (2, 5, 6) .
In a brief, preliminary communication (7), we showed that a2PI was adsorbed to fibrin when plasma was clotted and suggested that the adsorption might be another mechanism of the efficient inhibition of fibrinolysis by a2PI.
We now present evidence that a2PI is bound to fibrin by a covalent linkage formed by activated fibrinstabilizing factor (FSF, blood coagulation factor XIII, plasma transglutaminase), and suggest that the covalent binding of a2PI to fibrin contributes significantly to the stability of fibrin.
METHODS
Fibrinogen. Human fraction 1-4 prepared by the method of Blomback and Blomback (8) or human Cohn's fraction I (Green Cross Corp., Osaka) was used as fibrinogen preparation after removing contaminating plasminogen from the preparation using lysine-Sepharose (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) (9) . The concentration of FSF present in the solution of 250 mg/100 ml of fraction 1-4 or Cohn's fraction I was 50 or 80% ofnormal standard plasma, respectively, when assayed by an antibody neutralization method (10) using a Clotting Factor XIII-test kit supplied by Behringwerke AG, Marburg. Cold-insoluble globulin was not detected in the fraction 1-4 preparation by double immunodiffusion, single radial immunodiffusion or counter immunoelectrophoresis using specific antiserum against cold-insoluble globulin (11) . There was also no characteristic band of subunit cold-insoluble globulin with mol wt 215,000 when the preparation was analyzed by sodium dodecyl sulfate gel electrophoresis with reduction (11). Cohn's fraction I was clearly contaminated with cold-insoluble globulin. Fibrinogen was dissolved in barbital-buffered saline (0.005 M barbital-acetic acid-0. 14 M NaCl, pH 7.4) and the concentration was adjusted to 1.5% (wt/vol) clottable protein.
Thrombin. Purified thrombin was prepared from bovine thrombin preparation (Parke, Davis & Co., Detroit, Mich.) according to the method of Lundblad (12) , and was stored as a 200 U/ml solution in 50% glycerol at -200C.
Plasmin. Plasminogen was purified from human whole plasma by affinity chromatography using lysine-coupled Sepharose 4B (13) , and was activated with urokinase-coupled Sepharose according to the described method (5) . Total conversion of plasminogen to two-chain plasmin form was ascertained by sodium dodecyl sulfate gel electrophoresis with reduction (14) . Plasmin thus obtained was stored at -20°C as a 65 caseinolytic U/ml solution (15) a2PI. a2PI was purified by the described method (5) . The concentration of a2PI was determined by single radial immunodiffusion using monospecific antiserum to a2PI and a purified a2PI preparation with a known concentration as a standard (16) . Activity of a2PI was determined by a fibrinolytic method (5) .
Albumin. Human albumin (fraction V, fatty acid free) was purchased from Miles Laboratories, Inc., Elkhart, Ind.
Plasma and serum. Blood freshly drawn from antecubital veins was divided: one portion was immediately mixed with the powder of EDTA (Wako Pure Chemical Ind., Osaka) in a ratio of 1.86 mg EDTA to 1 ml blood and was centrifuged at 2,000 g for 20 min to prepare plasma. Another portion was allowed to stand in a glass test tube for 2 h at 37°C, and serum was separated from the clot by centrifugation. Serum was also obtained by clotting 1 ml of EDTA-plasma with 40 ul of thrombin (50 U/ml) or thrombin-calcium mixture (thrombin 50 U/ml, CaCl2, 0.375 M). FSF-deficient plasma was kindly supplied by Dr. M. Fujimaki, Department of Clinical Pathology, Tokyo Medical College. The blood was obtained from a patient with congenital deficiency of FSF and immediately mixed with 1/10 vol of 3.8% sodium citrate to obtain citrated plasma. When the fibrin formed by the addition of thrombin and calcium ions to this plasma was analyzed by sodium dodecyl sulfate gel electrophoresis (14) , no formation of y-chain dimer of fibrin was observed, indicating the absence of FSF in the patient's plasma. Serum was obtained by incubating 1 ml of plasma at 37°C for 2 h with 25 ,ul of 0.5 M CaCl2. a2PI-deficient plasma was obtained from a patient with congenital deficiency of a2PI (4) . Aprotinin (Trasylol, Bayer Chemical, Tokyo) was added to the plasma in a ratio of 5 IAI aprotinin (5,000 U/ml):1 ml plasma to avoid spontaneous fibrinolysis when the plasma was clotted.
Radioiodination of protein. Purified a2PI and fibrinogen (fraction 1-4) were radioiodinated by the method of Thorell and Johansson (17) or the solid-state lactoperoxidase method of David (18) , respectively, using lactoperoxidase (CalbiochemBehring Corp., American Hoechst Corp., San Diego, Calif.) and 125I-Na (17 Ci/ml) (New England Nuclear, Boston, Mass.). The labeled a2PI preparation had the radioactivity of 1.1
x 107 cpm/,ug. Specific activity of a2PI before and after radioiodination was 1136 U/A280 and 1,050 U/A2s0, respectively. a2PI concentration of the labeled a2PI preparation was 60 ixg/ml. The labeled fibrinogen preparation had a radioactivity of 6.3 x 104 cpm/Ig. Clottability (97%) was not changed, and fibrinogen concentration of the labeled preparation was 316 mg/100 ml clottable protein.
Measurement ofthe binding of a2PI tofibrin. When plasma was used, 1 ml of plasma was mixed in a counting vial for radioactivity with 5 Al of radiolabeled a2PI and the mixture was clotted by the addition of 40 Iul of thrombin (50 U/ml) or a thrombin-calcium mixture (thrombin 50 U/ml, CaCl2 0.375 M). The clotting mixture was incubated at 37°C for 30 min. When fibrinogen preparations were used, 135 ,tl of fibrinogen (1.5%) was mixed with 5 ,ul of radiolabeled a2PI, 40 Al of nonlabeled a2PI (1.5 mg/ml) and 810 Al of buffered saline containing calcium chloride or no calcium chloride. The mixture was clotted with 10 ,ul of thrombin (200 U/ml) and incubated at 37°C for 30 min. In some experiments 400 M1 of batroxobin (20 U/ml) were used instead of thrombin.
After counting the total radioactivity, the formed clot was separated by centrifugation. The clot was then squeezed with a bamboo stick against the wall of the tube to express as much fluid as possible. The fibrin was subsequently soaked in buffered saline to wash out unbound materials with frequent changes of buffered saline. The total volume of buffered saline used to wash one clot was 25 ml. After washing, the clot was counted for radioactivity. Radioactivity was counted by Auto-Well gamma system, Aloka JDC-752 (Aloka Co., Tokyo). The amount of Ca2PI bound to fibrin was calculated from the radioactivity remaining in the washed clot and expressed as a percentage of the original total radioactivity in the clotting mixture. The studies were carried out in triplicate. The original radioactivity in the clotting mixture was 80,817 +4,747 cpm.
Measurement of plasmin-induced clot lysis. 1.2 ml of fibrinogen (fraction 1-4, 9.8 mg/ml) was mixed with 40 ,l of radiolabeled fibrinogen. 100 ,ul of this mixture was mixed with 25 IL of a2PI (1.1 mg/ml or its dilutions) or buffered saline, 245 Al of buffered saline containing 2% human albumin, and 20 Al of calcium chloride (0.1 M). The mixture was clotted with 10 Ml of thrombin (100 U/ml) and incubated at 37°C for 30 min. The purpose of including albumin in the clotting mixture was to stabilize a2PI and preserve its inhibitor activity during the incubation. The clot was squeezed, washed, and counted for radioactivity in the same way as described in the preceding section except that the first two washes contained 2% albumin. Albumin was effective in reducing unspecific noncovalent binding of a2PI to fibrin. The clot was then placed in 360 gl buffered saline (0.05 M Tris-HCl-0.15 M NaCl, pH 7.4), to which 25 Al of plasmin (4.3 U/ml, 0.4 mg/ml) was added, and incubated at 370C for lysis. Aliquots of 50 ,AI were removed at intervals for radioactive counting. Results were expressed as percent release ofradiolabel, which was calculated from the counts, applying a correction for the influence of repeated subsampling upon the volume of the supematant. Controls were run replacing plasmin with buffered saline. The control values were constantly low (<5%) during the incubation, and the plasmin-induced release was calculated by subtracting the control value from that of the test. The radioactivity of the original clot was 710,417t20,951 cpm. In the parallel experiments, radiolabeled fibrinogen was replaced by radiolabeled a2PI and the binding ofa2PI to fibrin was estimated as described in the preceding section. Noncovalent binding of a2PI in the washed clot was estimated by eluting the washed clot with 8 M urea. Gel electrophoresis. Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis was performed with 5% polyacrylamide gels according to the method of Weber and Osbom (14) . Before electrophoresis, the proteins were denatured and reduced by incubation for 30 min at 100°C with 2% SDS and 5% 2-mercaptoethanol.
Immunoelectrophoresis. Immunoelectrophoresis was carried out in 1% agarose in pH 8.6 barbital buffer (I = 0.05) on a glass slide. Electrophoresis was run with a constant current of3 mA/cm width for 1 h. Specific antiserum ofrabbits against a2PI (5) was used.
Fluorescent photography. Photographs of gels containing proteins labeled with fluorescent amine, MDC, were taken with Fuji film ASA 400 (Fuji Film Co., Tokyo) and a yellow filter (Asahi Pentax filter 49 "Y2", Asahi Pentax Co., Tokyo); a long wavelength ultraviolet box (Ultra-violet Products, Inc., San Gabriel, Calif.) was the light source.
RESULTS
Difference of a2PI concentrations between plasma and serum. When 11 normal individuals were examined, a2PI concentration in serum was lower than that in plasma ofthe same individual and the difference was -24% on average of the concentration in plasma (Table I) . However, there was no appreciable difference observed between plasma and serum when FSFdeficient blood was examined (Table I) .
a2PI concentration in serum prepared by clotting plasma with thrombin plus calcium ions was compared with that in serum prepared by thrombin only. When nine pairs of the serum samples from normal individuals were examined, the serum samples prepared in the presence of calcium ions had lower concentrations of a2PI than those in the serum samples prepared in the absence of calcium ions and the average difference was 33% (Table II) . No appreciable difference was found between these two kinds ofserum samples ifthey were obtained from a patient with congenital deficiency of FSF (Table II) .
Binding of a2PI to fibrin. Binding of a2PI to fibrin was examined by clotting plasma with thrombin in the presence or absence of calcium ions. In the absence of calcium ions only about 2% of a2PI in normal plasma remained bound to fibrin after washing with buffered saline. In the presence of 5 mM calcium ions the binding was increased and -22% of a2PI in plasma were bound to fibrin when plasma was clotted (Table III) . Thus, the amount ofa2PI bound to fibrin was dependent on whether calcium ions were present or not when normal plasma was clotted. However, when FSF-deficient plasma was clotted, calcium-dependent binding of a2PI to fibrin was not evident and there was no significant difference of the binding between the presence and the absence of calcium ions (Table III) .
When a fibrinogen preparation (Fraction 14 or Cohn's fraction I) was clotted by thrombin in the presence of calcium ions, the differential binding of a2PI to fibrin was similarly observed as using normal plasma (Table  III) . The binding in the presence of 5 mM calcium ions was -10-fold greater than the binding in the ab- 2 Relationship between a2PI concentration and the binding of a2PI. 900 ,ul of a2PI-deficient citrated plasma, 40 ,1u of a2PI of various concentrations containing radiolabeled a2PI, 20 AIl of 0.5 M CaC12, and 40 ,ul of buffered saline containing 3 U of thrombin were mixed and incubated at 370C for 20 min. Fibrinogen concentration in the plasma was 200 mg/100 ml. The binding of a2PI to fibrin was determined as described in Methods. The amount of a2PI bound to fibrin was calculated from the binding ratio and the total amount of a2PI present in the clotting mixture. calcium ions was subjected to SDS gel electrophoresis after washing the clot. Distributions of protein and radioactivity in the gel are shown in Fig. 1 . Radioactivity was mainly distributed over the region of high molecular weight polymers of a-chain of cross-linked fibrin.
Influence of a2PI concentrations on the binding of a2PI. When a2PI was added in increasing amounts to a2PI-deficient plasma up to the normal concentration (6 mg/100 ml), the amount of a2PI bound to fibrin increased in direct proportion to the amount of a2PI added (Fig. 2) .
Influence offibrinogen concentration on the binding of a2PI. The binding of a2PI to fibrin was determined with various concentrations of fibrinogen in the clotting mixture. With a fixed concentration of a2PI and excess amounts of FSF, the amount of a2PI bound to fibrin was dependent on the concentration of fibrinogen until the fibrin is "saturated" with a2PI (Fig. 3) .
Effect of FSF concentration on the binding of a2PI to fibrin. Various amounts of FSF concentrates were added to FSF-deficient plasma. When these plasmas with various concentrations of FSF were clotted by thrombin and calcium ions, the amount of a2PI bound to fibrin was directly proportional to the amount of FSF added until FSF concentration reached -8% of normal concentration in plasma, where the increase started to level off (Fig. 4) .
Inhibition of the binding of a2PI by primary amines. Histamine and fluorescent primary amine, MDC, were tested for their effects on the binding of a2PI to fibrin. These primary amines are known to be substrates for activated FSF These amines inhibited the binding of a2PI in a dosedependent fashion. To see if a2PI was also a substrate for activated FSF, a2PI was incubated with FSF concentrate, thrombin, calcium ions, and MDC in the presence of reduced glutathion. The mixture was subsequently subjected to SDS gel electrophoresis and immunoelectrophoresis. The protein band of a2PI or the protein precipitated specifically with anti-a2PI antiserum were fluorescently labeled (Fig. 6) , indicating that the fluorescent amine was being incorporated into a2PI. The incorporation was catalyzed by activated FSF, because no fluorescent labeling was observed in the absence of calcium ions, thrombin, or FSF.
Resistance of a2PI-cross-linked fibrin to plasmin. Susceptibilities to plasmin digestion of fibrin crosslinked to a2PI and fibrin not cross-linked to a2PI were examined by clotting radiolabeled fibrinogen with thrombin and calcium ion in the presence or absence of a2PI. Fibrinogen concentration and the maximum concentration of a2PI used in the clotting mixture were 262 and 6.9 mg/100 ml, respectively. These are normal values in plasma. The fibrin clots thus formed were thoroughly washed to remove unbound a2PI. In the parallel experiments, noncovalently bound a2PI was found to be very low: <1% of the original amount of a2PI in the clotting mixture, whereas 30% was covalently linked to fibrin. The clots were subsequently subjected to plasmin-catalyzed fibrinolysis (Fig. 7) . Release of AMi Cmtration (pM) FIGURE 5 Inhibition ofa2PI binding by histamine and MDC. 2.5 mg of fibrinogen (fraction [1] [2] [3] [4] , 84 p.g of a2PI containing radiolabeled a2PI, various amounts of histamine or MDC, 5 ,umol of CaCl2 and 3 U of thrombin in buffered saline were mixed and incubated at 37°C for 20 min. The total volume was 1 ml. The binding of a2PI to fibrin was determined as described in Methods. radiolabel, which is an indicator of fibrinolysis, was suppressed by cross-linked a2PI, and the degree of suppression was dependent on the amount of cross-linked a2PI (Fig. 7) (Fig. 2, 3, and 4) . These findings together with the failure to elute the bound a2PI from fibrin with 8 M urea (7) suggest that a2PI is enzymatically cross-linked to fibrin by activated FSF. a2PI seemed to be cross-linked mainly to the crosslinked polymers of a-chain of fibrin because radiolabeled a2PI was found associated mainly with highly polymerized a-chains in SDS gel electrophoresis (Fig.  1) . Exact sites in the chains where a2PI can be linked are not known. Cold-insoluble globulin is also crosslinked to fibrin (20) , but a2PI cross-linking was not mediated by cold-insoluble globulin because fibrinogen preparation (fraction [1] [2] [3] [4] used in the present study was not contaminated by cold-insoluble globulin.
FSF belongs to the class of calcium ion-dependent enzymes called transglutaminases and catalyzes the transfer reaction involving lysyl residues in proteins and peptides as amine donors and glutamyl residues as amine acceptors, thus resulting in the formation of -y-glutamyl-E-lysine peptide bonds between adjacent fibrin monomers, converting noncovalently linked fibrin to a covalently linked form (19) . Various primary amines including synthetic fluorescent amines can be used as amine donors in this reaction and are known to inhibit competitively the enzymatic cross-linking of fibrin (21) . In the present study, these primary amines were shown to inhibit also the binding of a2PI to fibrin in a dose-dependent fashion (Fig. 5) . This is another evidence for FSF-catalyzed binding of a2PI to fibrin.
When a2PI was incubated with FSF, thrombin, and calcium ion in the presence of fluorescent amine donor, MDC, fluorescent labeling of a2PI took place (Fig. 6) ;-fibrin. Whether or not a2PI is also playing the part of amine donor in the reaction is not known at the present time. a2-Macro-globulin was also shown to be fluorescently labeled by FSF when plasma was clotted in the presence of MDC and calcium ion (22) . However, no evidence was found for cross-linking of a2-macroglobulin to fibrin when plasma was clotted (22) .
To determine if cross-linking of a2PI to fibrin makes fibrin less susceptible to plasmin-catalyzed fibrinolysis, fibrin cross-linked to a2PI and fibrin not cross-linked to a2PI were subjected to lysis by plasmin. Release of radiolabel from '251-labeled fibrin clots, which may be the most reliable indicator of fibrinolysis (23) , was suppressed by cross-linked a2PI and the degree of suppression was dependent on the amount of cross-linked a2PI (Fig. 7) . The amount of plasmin used was nearly equimolar to the maximum amount of cross-linked a2PI used in the experiments. Plasmin-induced fibrinolysis was almost totally suppressed by this amount of crosslinked a2PI (Fig. 7A) , suggesting that a2PI retains its full activity after its cross-linking to fibrin.
The amount of a2PI noncovalently bound to fibrin in the washed clot was very small (< 1% ofthe total amount of a2PI in the clotting mixture) and its contribution to the inhibition of plasmin was negligible since plasmin used was at least 30 times in molar excess of noncovalently bound a2PI. Furthermore, no significant difference in lysis rate of noncross-linked fibrin was observed whether the noncovalently bound a2PI was present or not (data not shown).
The controversial results reported by several authors regarding the influence of fibrin cross-linking on fibrinolysis could be explained at least partly by FSF catalyzed binding of a2PI to fibrin. It has been assumed that cross-linking by FSF makes fibrin less susceptible to lysis by fibrinolytic enzymes, especially to plasminogen activators (23) (24) (25) (26) (27) . However, recent studies using purified protein components revealed no difference in resistance to lysis of highly cross-linked and noncross-linked fibrin (28, 29) . In the former studies designed to give evidence for the increase of resistance to fibrinolysis by fibrin cross-linking, plasma rather than purified fibrinogen was used and therefore the reduced susceptibility of cross-linked fibrin to fibrinolysis might be explained by FSF catalyzed binding of a2PI to fibrin.
